78 Recruiting Studies Using Decitabine
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Decitabine
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Locally Advanced Unresectable Primary Central Chondrosarcoma
View Study & Checklist ➔ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Phase Chronic Myelogenous Leukemia
View Study & Checklist ➔Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
📍 Roswell Park Cancer Institute — Buffalo, New York
Advanced Fallopian Tube Carcinoma
View Study & Checklist ➔A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
📍 Children's Hospital of Central California — Madera, California
Acute Myeloid Leukemia
View Study & Checklist ➔Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
📍 City of Hope Medical Center — Duarte, California
Recurrent Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Recurrent Acute Biphenotypic Leukemia
View Study & Checklist ➔Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Myelomonocytic Leukemia
View Study & Checklist ➔Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Acute Myeloid Leukemia
View Study & Checklist ➔Tegavivint for the Treatment of Relapsed or Refractory Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Recurrent Leukemia
View Study & Checklist ➔Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
Solid Tumor
View Study & Checklist ➔Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
📍 Roswell Park Cancer Institute — Buffalo, New York
Recurrent Fallopian Tube Carcinoma
View Study & Checklist ➔Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Leukemia
View Study & Checklist ➔Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Acute Myeloid Leukemia
View Study & Checklist ➔Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
📍 O'Neal Comprehensive Cancer Center — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
📍 Allegheny Health Network — Pittsburgh, Pennsylvania
PTCL
View Study & Checklist ➔Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
📍 Brigham and Women's Hospital — Boston, Massachusetts
Myeloid Malignancy
View Study & Checklist ➔Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔Decitabine in Treating Patients With Myelofibrosis
📍 University of Chicago Comprehensive Cancer Center — Chicago, Illinois
Primary Myelofibrosis
View Study & Checklist ➔Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
📍 OHSU Knight Cancer Institute — Portland, Oregon
Acute Myeloid Leukemia
View Study & Checklist ➔Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
📍 Oregon Health Sciences University — Portland, Oregon
Myelodysplastic Syndromes
View Study & Checklist ➔Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Previously Treated Myelodysplastic Syndrome
View Study & Checklist ➔Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Chronic Myelomonocytic Leukemia
View Study & Checklist ➔Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
📍 St. Elizabeth Healthcare — Edgewood, Kentucky
Breast Adenocarcinoma
View Study & Checklist ➔Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia
📍 University Of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
Acute Myeloid Leukemia
View Study & Checklist ➔Pilot Study of Reduced Venetoclax Exposure
📍 Zuckerberg Cancer Center — New Hyde Park, New York
Acute Myeloid Leukemia in Remission
View Study & Checklist ➔FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
📍 City of Hope National Medical Center — Duarte, California
Advanced Hematologic Malignancy
View Study & Checklist ➔A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
📍 Boston Children's Hospital — Boston, Massachusetts
Acute Myeloid Leukemia
View Study & Checklist ➔Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
📍 Lafayette Family Cancer Center-EMMC — Brewer, Maine
Acute Myeloid Leukemia
View Study & Checklist ➔Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Recurrent Acute Lymphoblastic Leukemia
View Study & Checklist ➔Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Chronic Myelomonocytic Leukemia
View Study & Checklist ➔Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN
📍 Virginia Commonwealth University — Richmond, Virginia
Relapsed / Refractory AML
View Study & Checklist ➔Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
📍 Northside Hospital, Inc. — Atlanta, Georgia
Acute Myeloid Leukemia
View Study & Checklist ➔Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
📍 Houston Methodist Neal Cancer Center — Houston, Texas
Acute Myeloid Leukemia (AML)
View Study & Checklist ➔A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
📍 University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
Ovarian Cancer
View Study & Checklist ➔ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
📍 Washington University School of Medicine — St Louis, Missouri
Acute Myeloid Leukemia
View Study & Checklist ➔Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Recurrent B-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
📍 Moffitt Cancer Center — Tampa, Florida
Acute Myeloid Leukemia
View Study & Checklist ➔Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Acute Myeloid Leukemia
View Study & Checklist ➔Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
📍 MD Anderson Cancer Center — Houston, Texas
Lymphodepleting Chemotherapy
View Study & Checklist ➔Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
📍 Illinois CancerCare-Bloomington — Bloomington, Illinois
Acute Myeloid Leukemia
View Study & Checklist ➔Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
📍 Mayo Clinic Health Systems-Mankato — Mankato, Minnesota
Clonal Cytopenia of Undetermined Significance
View Study & Checklist ➔Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes
📍 West Virginia University Cancer Institute — Morgantown, West Virginia
Myelodysplastic Syndromes
View Study & Checklist ➔A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
Myeloid Malignancies
View Study & Checklist ➔Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
📍 Banner University Medical Center - Tucson — Tucson, Arizona
Acute Myeloid Leukemia
View Study & Checklist ➔A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
📍 Children's Hospital of Alabama — Birmingham, Alabama
Acute Myeloid Leukemia Post Cytotoxic Therapy
View Study & Checklist ➔ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
📍 Montefiore Einstein Medical Center — The Bronx, New York
MDS
View Study & Checklist ➔Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
📍 Mayo Clinic Arizona — Phoenix, Arizona
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
View Study & Checklist ➔A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
📍 Scripps Green Hospital — La Jolla, California
Acute Myeloid Leukemia, in Relapse
View Study & Checklist ➔Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
📍 University of Alabama at Birmingham — Birmingham, Alabama
Myeloid Malignancy
View Study & Checklist ➔Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Acute Myeloid Leukemia
View Study & Checklist ➔Avapritinib With Decitabine in Patients With SM-AHN
📍 Mayo Clinic - Arizona — Phoenix, Arizona
Systemic Mastocytosis With an Associated Hematologic Neoplasm
View Study & Checklist ➔Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
📍 Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio
Myelodysplastic Syndromes
View Study & Checklist ➔High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
📍 University of Iowa Health Care — Iowa City, Iowa
Acute Myeloid Leukemia
View Study & Checklist ➔Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
📍 University of California Davis Health (UC Davis Health) — Sacramento, California
Myelodysplastic Syndromes
View Study & Checklist ➔Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
📍 UCSF-Fresno — Clovis, California
Acute Myeloid Leukemia
View Study & Checklist ➔Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer
📍 Mayo Clinic in Florida — Jacksonville, Florida
Human Papillomavirus-Negative Neck Squamous Cell Carcinoma
View Study & Checklist ➔Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
View Study & Checklist ➔Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
📍 Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
Myelodysplastic Syndrome
View Study & Checklist ➔Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
📍 University of Miami — Miami, Florida
Mutant IDH1 Inhibitor Olutasidenib
View Study & Checklist ➔A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
📍 UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
Accelerated Phase Myeloproliferative Neoplasm
View Study & Checklist ➔Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
📍 Mayo Clinic — Jacksonville, Florida
Myelodysplastic Syndromes
View Study & Checklist ➔A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
📍 MD Anderson Cancer Center — Houston, Texas
Advanced Chronic Myeloid Leukemia
View Study & Checklist ➔Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
📍 University of Texas MD Anderson Cancer Center — Houston, Texas
Leukemia
View Study & Checklist ➔Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
📍 Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio
Myeloid Malignancy
View Study & Checklist ➔MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Acute Myeloid Leukemia
View Study & Checklist ➔Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
📍 Loyola University Medical Center — Maywood, Illinois
Ovarian Cancer
View Study & Checklist ➔Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
📍 Yale University — New Haven, Connecticut
Acute Myeloid Leukemia
View Study & Checklist ➔FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
📍 Montefiore Medical Center — The Bronx, New York
Acute Myeloid Leukemia
View Study & Checklist ➔Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Accelerated Phase Myeloproliferative Neoplasm
View Study & Checklist ➔A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
📍 MD Anderson Cancer Center — Houston, Texas
T-cell Acute Lymphoblastic Leukemia
View Study & Checklist ➔Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔